Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Xeris Biopharma is a specialty pharmaceutical company focused on ready-to-use injectable and infusible therapies for rare endocrine and neurological conditions. The company commercializes Gvoke (ready-to-use glucagon for severe hypoglycemia), Keveyis (primary periodic paralysis), Recorlev (Cushing's syndrome), and acquired Baqsimi (nasal powder glucagon) in 2024. With 81.9% gross margins but negative operating margins, the company is in a growth-to-profitability transition phase, scaling commercial operations while managing a negative shareholder equity position.
Xeris generates revenue through direct sales of FDA-approved specialty pharmaceuticals targeting rare endocrine conditions with limited competition. The company focuses on ready-to-use formulations that offer convenience advantages over traditional reconstituted products. Pricing power derives from orphan drug designations, limited generic competition in rare disease markets, and insurance reimbursement for medically necessary treatments. The 81.9% gross margin reflects specialty pharma economics with low manufacturing costs relative to pricing, though the company remains unprofitable due to commercial infrastructure buildout, sales force expansion, and ongoing R&D investments. Revenue growth of 23.9% indicates successful market penetration, but negative operating cash flow signals the company is still investing heavily to scale.
Gvoke prescription volume trends and market share gains versus Lilly's Baqsimi and Amphastar's generic glucagon emergency kits
Baqsimi integration success post-acquisition including revenue synergies, formulary access retention, and cross-selling effectiveness
Recorlev commercial uptake in Cushing's syndrome market (estimated 20,000 US patients) and potential label expansions
Path to profitability milestones including quarterly operating expense trends, EBITDA breakeven timing, and cash runway visibility
Pipeline development updates for XP-8121 (continuous subcutaneous hydrocortisone infusion for adrenal insufficiency) and other formulation technologies
Payer coverage decisions and formulary positioning for key products affecting reimbursement rates and patient access
Competitive threat from biosimilar or generic glucagon products eroding Gvoke/Baqsimi market share, particularly as patents expire or regulatory exclusivity periods end
Payer reimbursement pressure including formulary exclusions, prior authorization requirements, or step-edit protocols that could limit patient access and revenue growth
FDA regulatory risk for pipeline assets including potential clinical trial failures, approval delays, or post-market safety issues requiring label changes or withdrawals
Rare disease market size constraints limiting total addressable market for orphan products, with Cushing's syndrome affecting approximately 20,000 US patients and periodic paralysis even smaller populations
Eli Lilly's established presence in diabetes care with broader product portfolio and stronger payer relationships potentially limiting Gvoke market penetration
Amphastar and other generic manufacturers offering lower-cost glucagon alternatives that could pressure pricing or require increased rebates to maintain formulary access
Larger specialty pharma companies (Recordati, Corcept) with deeper resources competing in Cushing's syndrome market and potentially outspending on physician education and market access
Negative shareholder equity of $1.2B (implied from -1448.3x P/B ratio) reflecting accumulated deficits and limiting financial flexibility for acquisitions or investments without dilutive equity raises
Negative operating and free cash flow requiring continued capital raises or achievement of profitability to sustain operations, with current cash burn rate creating potential dilution risk for existing shareholders
Limited debt capacity given negative equity position, forcing reliance on equity markets for growth capital in a potentially unfavorable rate environment for unprofitable biotech valuations
low - Specialty pharmaceuticals for rare endocrine conditions are medically necessary treatments with inelastic demand. Patients with severe hypoglycemia, Cushing's syndrome, or periodic paralysis require treatment regardless of economic conditions. Insurance coverage (commercial, Medicare Part D, Medicaid) insulates most patients from direct price sensitivity. However, high-deductible health plan penetration during economic downturns could marginally affect patient out-of-pocket costs and adherence. The company's growth is more dependent on clinical adoption, formulary access, and market share dynamics than GDP fluctuations.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for unprofitable growth companies, particularly affecting the 4.4x P/S multiple as investors demand faster paths to profitability. (2) Potential future financing needs become more expensive if the company requires additional capital before reaching cash flow breakeven, though the 1.93x current ratio suggests near-term liquidity is adequate. The negative shareholder equity position limits debt capacity, making equity financing more likely. Lower rates would benefit valuation multiples and reduce future financing costs.
Minimal direct credit exposure as the business model does not involve lending or significant receivables risk. Revenue is primarily from pharmacy benefit managers, wholesalers, and specialty pharmacies with established payment terms. The negative debt-to-equity ratio (-44.35) reflects negative shareholder equity rather than high leverage, indicating accumulated losses rather than debt burden. Credit market conditions could indirectly affect access to growth capital if needed, but the company's funding needs are more equity-dependent given the balance sheet structure.
growth - The 81.7% one-year return and 23.9% revenue growth attract growth investors focused on commercial-stage biotech companies scaling revenue with paths to profitability. The negative margins and cash flow indicate this is a pre-profitable growth story rather than value or income investment. Momentum traders are drawn to the volatility and strong recent performance. The specialty pharma focus on rare diseases with orphan drug economics appeals to biotech-focused growth funds. Not suitable for value investors given negative book value, or income investors given no dividend and cash burn.
high - Small-cap biotech ($1.2B market cap) with binary catalysts including product launches, clinical trial results, regulatory decisions, and quarterly earnings beats/misses create significant volatility. The 81.7% one-year return alongside -4.5% six-month return demonstrates sharp swings. Unprofitable companies with negative cash flow trade on sentiment and forward expectations rather than stable earnings, amplifying volatility. Limited analyst coverage and institutional ownership in small-cap biotech increases price sensitivity to news flow. Options market activity and short interest can further amplify moves.
